GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » Cash Flow from Financing

China National Accord Medicines (SZSE:000028) Cash Flow from Financing

: ¥-2,408 Mil (TTM As of Dec. 2023)
View and export this data going back to 1993. Start your Free Trial

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Dec. 2023, China National Accord Medicines paid ¥0 Mil more to buy back shares than it received from issuing new shares. It spent ¥191 Mil paying down its debt. It paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received ¥4 Mil from paying cash dividends to shareholders. It spent ¥206 Mil on other financial activities. In all, China National Accord Medicines spent ¥393 Mil on financial activities for the three months ended in Dec. 2023.


China National Accord Medicines Cash Flow from Financing Historical Data

The historical data trend for China National Accord Medicines's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China National Accord Medicines Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,000.22 -1,740.42 -1,871.64 -1,507.76 -2,407.64

China National Accord Medicines Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Financing Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -565.75 -82.58 -1,327.10 -604.97 -392.99

China National Accord Medicines Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

China National Accord Medicines's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

China National Accord Medicines's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-2,408 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China National Accord Medicines  (SZSE:000028) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

China National Accord Medicines's issuance of stock for the three months ended in Dec. 2023 was ¥0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

China National Accord Medicines's repurchase of stock for the three months ended in Dec. 2023 was ¥0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

China National Accord Medicines's net issuance of debt for the three months ended in Dec. 2023 was ¥-191 Mil. China National Accord Medicines spent ¥191 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

China National Accord Medicines's net issuance of preferred for the three months ended in Dec. 2023 was ¥0 Mil. China National Accord Medicines paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

China National Accord Medicines's cash flow for dividends for the three months ended in Dec. 2023 was ¥4 Mil. China National Accord Medicines received ¥4 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

China National Accord Medicines's other financing for the three months ended in Dec. 2023 was ¥-206 Mil. China National Accord Medicines spent ¥206 Mil on other financial activities.


China National Accord Medicines Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


China National Accord Medicines (SZSE:000028) Business Description

Traded in Other Exchanges
Address
No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029
China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines